Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "biopsy"

43 News Found

DiaCarta receives CE/IVD for its Covid-19 screening test
Biotech | September 10, 2021

DiaCarta receives CE/IVD for its Covid-19 screening test

This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing

Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment
Digitisation | August 11, 2021

Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment

The aim is to create new genomics solutions that could combat cancer and advance market access

Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Digitisation | August 10, 2021

Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests

Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection

Latest Stories

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging